Eli Lilly and Company

02/07/2025 | Press release | Distributed by Public on 02/07/2025 05:45

Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years